Abeona Therapeutics Inc (NASDAQ:ABEO) CFO Joseph Walter Vazzano Sells 17,795 Shares

Abeona Therapeutics Inc (NASDAQ:ABEO) CFO Joseph Walter Vazzano sold 17,795 shares of the company’s stock in a transaction dated Friday, June 6th. The stock was sold at an average price of $6.76, for a total value of $120,294.20. Following the sale, the chief financial officer now owns 491,246 shares of the company’s stock, valued at approximately $3,320,822.96. This trade represents a 3.50% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Abeona Therapeutics Stock Up 4.0%

Shares of ABEO opened at $6.74 on Friday. The firm has a market capitalization of $344.80 million, a price-to-earnings ratio of -2.51 and a beta of 1.54. The company has a debt-to-equity ratio of 0.31, a quick ratio of 6.12 and a current ratio of 6.12. The business’s fifty day moving average price is $5.56 and its two-hundred day moving average price is $5.58. Abeona Therapeutics Inc has a 52 week low of $3.93 and a 52 week high of $7.32.

Abeona Therapeutics (NASDAQ:ABEO) last announced its quarterly earnings data on Thursday, May 15th. The biopharmaceutical company reported ($0.24) EPS for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.11. On average, analysts predict that Abeona Therapeutics Inc will post -1.16 earnings per share for the current year.

Analysts Set New Price Targets

Several analysts recently weighed in on ABEO shares. HC Wainwright increased their target price on Abeona Therapeutics from $15.00 to $20.00 and gave the company a “buy” rating in a research note on Wednesday, April 30th. Alliance Global Partners restated a “buy” rating on shares of Abeona Therapeutics in a research note on Thursday, May 15th. Stifel Nicolaus decreased their target price on Abeona Therapeutics from $21.00 to $20.00 and set a “buy” rating for the company in a research note on Friday, May 16th. Oppenheimer started coverage on Abeona Therapeutics in a research note on Monday, June 2nd. They set an “outperform” rating and a $19.00 target price for the company. Finally, Wall Street Zen downgraded Abeona Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, May 15th. One investment analyst has rated the stock with a sell rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $19.25.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ABEO. Adage Capital Partners GP L.L.C. lifted its holdings in Abeona Therapeutics by 20.1% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 3,902,360 shares of the biopharmaceutical company’s stock worth $21,736,000 after acquiring an additional 652,366 shares in the last quarter. Western Standard LLC lifted its holdings in Abeona Therapeutics by 22.8% during the fourth quarter. Western Standard LLC now owns 2,084,418 shares of the biopharmaceutical company’s stock worth $11,610,000 after acquiring an additional 386,321 shares in the last quarter. Jane Street Group LLC lifted its holdings in Abeona Therapeutics by 894.8% during the fourth quarter. Jane Street Group LLC now owns 131,478 shares of the biopharmaceutical company’s stock worth $732,000 after acquiring an additional 118,262 shares in the last quarter. 683 Capital Management LLC lifted its holdings in Abeona Therapeutics by 17.3% during the fourth quarter. 683 Capital Management LLC now owns 791,845 shares of the biopharmaceutical company’s stock worth $4,411,000 after acquiring an additional 116,845 shares in the last quarter. Finally, Newtyn Management LLC lifted its holdings in Abeona Therapeutics by 26.3% during the first quarter. Newtyn Management LLC now owns 480,000 shares of the biopharmaceutical company’s stock worth $2,285,000 after acquiring an additional 100,000 shares in the last quarter. 80.56% of the stock is currently owned by institutional investors.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.